when expanded out to 25 names) included Air Products & Chemicals APD, American Express AXP, Best Buy BBY, Forest Laboratories FRX, Freeport-McMoRan Copper & Gold FCX, Kohl's KSS, Mondelez International MDLZ, Morgan Stanley MS, Oracle
MADRID, May 2 (Reuters) - Spain's Almirall and Forest Laboratories said on Thursday that results of a second phase III clinical trial for a new inhaler were positive and they will seek regulatory approval to sell the drug by the end of the year.
Forest Laboratories ( FRX ) Q4 2013 Earnings Call April 23, 2013 10:00 am ET Executives ..... a href='http://seekingalpha.com/article/1363111- forest - laboratories -management-discusses-q4-2013-results-earnings-call
MADRID, April 16 (Reuters) - Spain's Almirall and Forest Laboratories said results of a first phase III clinical trial for Almirall's Genuair inhaler were positive and they would seek regulatory approval to sell the drug if further results proved positive.
Carl Ichan-backed Forest Laboratories ( FRX ) and Almirall say a combination COPD treatment of aclidinium and formoterol met both endpoints in a Phase III clinical trial
company's lead investigational drug plecanatide can "achieve revenue parity" with Ironwood ( IRWD -0.5% ) and Forest Laboratories ' ( FRX -0.2% ) Linzess, an FDA approved treatment for constipation. Post your comment!
Forest Laboratories , Inc. ( FRX ) March 13, 2013 10:15 am ET Executives Francis ..... a href='http://seekingalpha.com/article/1270401- forest - laboratories -inc-presents-at-barclays-global-healthcare-conference
Forest Laboratories , Inc. ( FRX ) February 27, 2013 ..... I am very excited to be hosting Forest Laboratories this morning, and we're very ..... seekingalpha.com/article/1231881- forest - laboratories -inc-presents-at-citi
By Pharma Reports: Forest Laboratories ( FRX ) launched Lexapro , escitalopram selective serotonin reuptake inhibito r (SSRI) , in September 2002. Lexapro quickly
weak pipeline increases the likelihood that AstraZeneca will look for a major acquisition in 2013, and we think Forest Laboratories FRX is a likely target, as its valuation looks attractive and the firm holds several recently approved drugs